中国实用外科杂志

中国实用外科杂志 ›› 2022, Vol. 42 ›› Issue (12): 1397-1400.DOI: 10.19538/j.cjps.issn1005-2208.2022.12.11

• 论著 • 上一篇    下一篇

基于分子分型的年轻乳腺癌病人临床病理特征及长期预后研究

班    雪1，2，王思源1，杨后圃1，彭    媛1，王朝斌1，刘    淼1，谢    菲1，王    殊1   

  1. 1北京大学人民医院乳腺中心，北京100044；2北京市第二医院，北京 100031
  • 出版日期:2022-12-01 发布日期:2022-12-27

  • Online:2022-12-01 Published:2022-12-27

摘要： 目的    分析不同分子亚型年轻乳腺癌病人临床病理特征及其与预后的关系。方法    回顾性分析2006年9月至2013年2月北京大学人民医院乳腺中心诊治的年轻女性乳腺癌病人临床病理资料。分析不同分子分型年轻乳腺癌病人的远期无病生存率和总生存率。结果    共263例病人纳入研究，中位随访127个月。10年无病生存率为77.9%，10年总生存率为91.3%。其中Luminal A、Luminal B、人类表皮生长因子受体-2（HER-2）过表达和三阴型4种分子亚型病人 10 年无病生存率分别为87.7%、69.4%、84.2%和75.0%（χ2=6.404，P=0.006）；10年总生存率分别为96.3%、100.0%、87.1%和88.2%（χ2=4.116，P=0.026）。不同分子亚型的年轻乳腺癌病人的组织学分级、肿瘤分期存在显著差异，其中三阴型病人组织学Ⅲ级、T3的比例更高（χ2=73.91，P＜0.01）。结论    不同分子分型的年轻乳腺癌病人临床病理特征及预后特征存在显著差异，三阴型及Luminal B型病人预后相对较差。

关键词: 乳腺癌, 年轻女性, 分子分型, 临床特征, 预后分析

Abstract: Clinicopathological features and long-term prognosis analysis of different molecular subtypes of breast cancer in young women        BAN Xue, WANG Si-yuan, YANG Hou-pu, et al.  Brest Disease Center, Peking University People’s Hospital, Beijing 100044, China; The Second Hospital of Beijing, Beijing 100031, China
Corresponding author：XIE Fei，E-mail: xiefei@pkuph.edu.cn
Abstract    Objective    To analyze the relationship between the clinicopathological feature and prognosis of young Chinese breast cancer patients with different molecular subtypes. Methods    The clinical data of young breast cancer patients treated in The Breast Center of Peking University People's Hospital from September 2006 to February 2013 were retrospectively analyzed. The clinicopathological characteristic of patients with different molecular types were analyzed. Disease-free survival and overall survival of young breast cancer patients with different molecular types was analyzed. Results    A total of 263 young breast cancer patients were studied, and a median follow-up was 127 months. The ten-year disease-free survival rate was 77.9%, and the overall survival rate was 91.3%. The disease-free survival rates of Luminal A, Luminal B, HER-2-enriched and triple-negative patients were 87.7%, 69.4%, 84.2% and 75.0%( χ2=6.404, P=0.006) ，respectively, the ten-year overall survival rates were 96.3%, 100.0%, 87.1% and 88.2%( χ2=4.116, P=0.026), respectively. There were significant differences in the histological grade and clinical stage. The proportion of histological grade Ⅲ and T3 stage was higher in patients with triple-negative subtype( χ2=73.91, P＜0.01) . Conclusion   There were significant differences in the clinicopathological feature and prognosis of young breast cancer patients with different molecular types in China. The prognosis in triple-negative and Luminal B subtype patients is relatively poor.

Key words: breast cancer, young woman, molecular subtype, clinicopathological feature, prognosis analysis